{rfName}
CD

Indexed in

License and use

Citations

57

Altmetrics

Analysis of institutional authors

Consuegra-Fernandez MAuthorAranda FAuthorSimoes, InesAuthorOrta MAuthorLozano FCorresponding Author

Share

Publications
>
Article

CD5 as a target for immune-based therapies

Publicated to:Critical Reviews In Immunology. 35 (2): 85-115 - 2015-01-01 35(2), DOI: 10.1615/critrevimmunol.2015013532

Authors: Consuegra-Fernandez, Marta; Aranda, Fernando; Simoes, Ines; Orta, Marc; Sarukhan, Adelaida; Lozano, Francisco

Affiliations

Departament de Biologia Cellular, Immunologia i Neurociències, Universitat de Barcelona, Barcelona, Spain - Author
Group of Immune Receptors of the Innate and Adaptive System, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain - Author
Hosp Clin Barcelona, Serv Immunol, Barcelona, Spain - Author
INSERM, Paris, France - Author
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain - Author
Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France - Author
Servei d’Immunologia, Hospital Clínic de Barcelona, Barcelona, Spain - Author
Univ Barcelona, Fac Med, Dept Biol Cellular Immunol & Neurociencies, Barcelona 7, Spain - Author
See more

Abstract

CD5 was one of the first surface receptors described for mouse and human T lymphocytes. Since then, it has been found to be highly expressed by regulatory T cells and a subpopulation of regulatory B cells, to be physically associated with the T- and B-cell antigen receptors, to negatively modulate TCR- and BCR-mediated signals, and to bind certain pathogen-associated molecular patterns. These findings position CD5 as an attractive target for developing immunotherapies aimed at either boosting or dampening ongoing immune responses. Here the available data on the function of CD5 and its involvement in the regulation of immune responses in health and disease are reviewed, as well as the evidence for and future challenges in developing therapeutic strategies aimed at targeting CD5 for autoimmune diseases, cancer, and infections.

Keywords

acute lymphoblastic-leukemiaanti-cd5 monoclonal-antibodiesautoimmunitybone-marrow-transplantationcancercd5chronic lymphocytic-leukemiaexperimental autoimmune encephalomyelitisfamilial hemophagocytic lymphohistiocytosisimmunotherapyinfectionregulatory t-cellsricin-a-chainversus-host-diseaseAnimalsAntigen expressionAntigen functionAntigen structureArticleAutoimmune diseasesAutoimmune nephropathyAutoimmunityB lymphocyte activationB-lymphocyte subsetsB-lymphocytes, regulatoryCancerCd5Cd5 antigenCd5 antigensCell survivalGenetic polymorphismGraft versus host reactionHemopoietic stem cell transplantationHumanHumansImmunological toleranceImmunoregulationImmunotherapyInfectionInfectionsInflammatory bowel diseaseInsulin dependent diabetes mellitusKidney diseaseLymphocyte activationMiceMultiple sclerosisMycosisNeoplasmNeoplasmsNonhumanPriority journalRheumatoid arthritisScavenger receptorStem cell transplantationSystemic lupus erythematosusSystemic-lupus-erythematosusT lymphocyte activationT-lymphocytes, regulatoryVirus infection

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Critical Reviews In Immunology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3.16, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-29, the following number of citations:

  • WoS: 20
  • Scopus: 22
  • Europe PMC: 15

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-29:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 55.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 55 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Consuegra Fernandez, Marta) and Last Author (Lozano Soto, Francisco).

the author responsible for correspondence tasks has been Lozano Soto, Francisco.